5 financements - 839 861€

données disponibles depuis 2018

2021

  1. DELETE. ImproveD procEdural workfLow for cathETEr ablation

    euro 202 660,00

  2. COMBATBIL

    euro 150 682,00

2020

  1. GSK BIOBADALER

    euro 173 880,00

  2. Estudio piloto para evaluar el potencial uso de la ivermecti

    euro 37 239,00

2018

  1. Phase I- II Study of intratumoral urelumab combined with niv

    euro 275 400,00